• Home
  • About us
  • Contact Us
  • Date/Time
  • Login
  • Subscribe

logo

  • Home
  • Politics
  • Economics & Finance
  • World
  • Arts & Books
  • Life
  • Science
  • Philosophy
  • Subscribe
  • Events
Home
  • Home
  • Blogs
  • Politics
  • Economics & Finance
  • World
  • Arts & Books
  • Life
  • Science
  • Philosophy
  • Subscribe
  • Events
  • Home
  • Science & Technology

Too much information

Good science starts with a hypothesis. But the human genome project didn’t have one

by Philip Ball / May 26, 2010 / Leave a comment
  • Facebook
  • Twitter
  • Linkedin
  • Email

The devil is in the detail: a circular computer “scanner” reads sections of DNA at the California Institute of Technology

Ten years ago, the first draft of the sequence of the human genome was heralded as the dawn of a new era of genetic medicine. According to Francis Collins, leader of the International Human Genome Sequencing Consortium (IHGSC) and now head of the US National Institutes of Health, the knowledge gained by the sequencing effort would eventually allow doctors to tailor cures to a patient’s individual genetic profile—a vision he suggested could become reality by 2010.

You might have noticed that it hasn’t. The medical impact of the human genome project (HGP) has so far been negligible. Collins’s claim in 2001 that “new gene-based ‘designer drugs’ will be introduced to the market for diabetes mellitus, hypertension, mental illness and many other conditions” no longer seems an inevitable result of decoding all the 21,000 or so human genes. So were we misled?

Not exactly. But the distance between promises and achievements reflects the fact that the HGP was, like the moon landings, a triumph of technological capability rather than scientific understanding.

It is normal for promises of scientific advances to be slow to deliver. And there’s no question that knowing the sequence of all 3bn of the basic building blocks of our DNA will aid research into human origins and evolution, demographics and disease. One of the technological spin-offs of the HGP is a vast improvement in sequencing techniques, which brought the project to a conclusion sooner (and at lower cost) than expected. This was partly due to the galvanising force of competition between the publicly-funded IHGSC project, and a private effort to sequence the genome by the US company Celera Genomics, led by the entrepreneur Craig Venter. Although we should be wary of emulating one of the justifications offered for human space flight—that it helps us learn about the effects of putting people in space—these techniques have put affordable personal genome sequencing on the horizon, and are contributing to an explosion in genomic data throughout the biological world.

But why haven’t these data been translated into new medicines, the real selling point of the HGP? Partly because shifting from knowledge of a disease-linked gene to a viable therapy has proved immensely challenging, even for a disease such as cystic fibrosis that is caused by a single faulty gene.…

YOU’VE HIT THE LIMIT

You have now reached your limit of 3 free articles in the last 30 days.
But don’t worry! You can get another 7 articles absolutely free, simply by entering your email address in the box below.

When you register we’ll also send you a free e-book—Writing with punch—which includes some of the finest writing from our archive of 22 years. And we’ll also send you a weekly newsletter with the best new ideas in politics and philosophy of culture, which you can of course unsubscribe from at any time







Prospect may process your personal information for our legitimate business purposes, to provide you with our newsletter, subscription offers and other relevant information.

Click to learn more about these interests and how we use your data. You will be able to object to this processing on the next page and in all our communications.

6296336335df3c8bd445307.25670966

Go to comments

Related articles

Share with friends
  • Facebook
  • Twitter
  • Linkedin
  • Email

Comments

  1. Jonathan Norton
    May 26, 2010 at 15:43
    I think Barry Commoner was making these points quite a few years ago.

Prospect's free newsletter

The big ideas that are shaping our world—straight to your inbox. PLUS a free e-book and 7 articles of your choosing on the Prospect website.

Prospect may process your personal information for our legitimate business purposes, to provide you with our newsletter, subscription offers and other relevant information. Click here to learn more about these purposes and how we use your data. You will be able to opt-out of further contact on the next page and in all our communications.

This Month's Magazine

Perspiciatis unde omnis iste natus.

A pint with Mr Wetherspoon, the wisdom of Clive James, inside the new arms race. Plus: A short story by Kamila Shamsie, and the new ideas for 2020

Subscribe

Most Popular

  • Read
  • Commented

The sinister threat to human rights buried in the Conservative manifesto

What was the general election turnout? (And four other statistics to know)

Ivan Rogers on "nonsense" predictions and why Johnson will not pivot to a softer Brexit

Six reasons why the Left need not despair

An independent Scotland in Europe?

Boris Johnson unbound: A British tragedy?

3 Comments

Ivan Rogers on Brexit: the worst is yet to come

3 Comments

John le Carré's post-Cold War vision is shot through with a sense of longing

2 Comments

How dare those signed up to hard Brexit lecture Labour on the economy?

2 Comments

Could this psychological theory explain why we’ll never let Brexit go?

1 Comments

About this author

Philip Ball
Philip Ball is a science writer
  • Follow Philip on:
  • Twitter
More by this author

More by Philip Ball

Where has all the sperm gone?
July 31, 2018
Is there life on Mars? A staggering new find just improved the odds
July 25, 2018
A scientist's crisis of faith
July 16, 2018

Next Prospect events

  • Details

    Prospect Book Club - David Lammy

    London, 2020-03-19

  • Details

    Prospect Book Club - Jack Shenker

    2020-02-17

  • Details

    Prospect Book Club - Amelia Gentleman

    2020-01-27

See more events

Sponsored features

  • Delivering the UK's invisible infrastructure project

  • Future of Aid: the full report

  • A forest fund for the future

  • A new humanitarianism for the modern age

  • The future of sustainable economic development

PrimeTime

The magazine is owned and supported by the Resolution Group, as part of its not-for-profit, public interest activities.

Follow us
  • Facebook
  • Twitter
  • Google+
  • RSS

Editorial

Editor: Tom Clark
Deputy Editor: Steve Bloomfield
Managing Editor (Arts & Books): Sameer Rahim
Head of Digital: Stephanie Boland
Digital Assistant: Rebecca Liu
Production Editor & Designer: Chris Tilbury
Commissioning Editor: Alex Dean
Creative Director: Mike Turner
US Writer-at-Large: Sam Tanenhaus

Commercial

Commercial Director: Alex Stevenson
Head of Marketing: Paul Mortimer
Marketing and Circulation Executive: Susan Acan
Head of Events: Victoria Jackson
Events Project Manager: Nadine Prospere
Head of Advertising Sales: Adam Kinlan 020 3372 2934
Senior Account Manager: Patrick Lappin 020 3372 2931
Head of Finance and Resources: David de Lange

  • Home
  • Advertising
  • Contact Us
  • Privacy Policy
  • Terms and Conditions
  • Acceptable Use Policy
© Prospect Publishing Limited
×
Login
Login with your subscriber account:
You need a valid subscription to login.
I am
Remember Me


Forgotten password?

Or enter with social networking:
Login to post comments using social media accounts.
  • With Twitter
  • Connect
  • With Google +
×
Register Now

Register today and access any 7 articles on the Prospect’s website for FREE in the next 30 days..
PLUS find out about the big ideas that will shape our world—with Prospect’s FREE newsletter sent to your inbox. We'll even send you our e-book—Writing with punch—with some of the finest writing from the Prospect archive, at no extra cost!

Not Now, Thanks

Prospect may process your personal information for our legitimate business purposes, to provide you with our newsletter, subscription offers and other relevant information.

Click to learn more about these interests and how we use your data. You will be able to object to this processing on the next page and in all our communications.

×
You’ve got full access!

It looks like you are a Prospect subscriber.

Prospect subscribers have full access to all the great content on our website, including our entire archive.

If you do not know your login details, simply close this pop-up and click 'Login' on the black bar at the top of the screen, then click 'Forgotten password?', enter your email address and press 'Submit'. Your password will then be emailed to you.

Thank you for your support of Prospect and we hope that you enjoy everything the site has to offer.

This site uses cookies to improve the user experience. By using this site, you agree that we can set and use these cookies. For more details on the cookies we use and how to manage them, see our Privacy and Cookie Policy.